NNC 01-0687

NNC 01-0687 (also known as ADX-10061, CEE-03-310, or NNC-687) is a selective dopamine D₁-like receptor antagonist of the benzazepine group which was under development as an experimental antipsychotic for the treatment of schizophrenia but was never marketed.^[1][2][3] Its development for schizophrenia was discontinued due to lack of effectiveness in clinical trials.^[2][4]

NNC 01-0687

Clinical data
Other names	ADX-10061; CEE 03-310; CEE-310; NNC 01-687; NNC-687; NO-687
Drug class	Dopamine D1-like receptor antagonist
Identifiers
IUPAC name (5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-1,2,4,5-tetrahydro-3-benzazepin-7-ol
CAS Number	128022-68-4
PubChem CID	164252
DrugBank	DB05419
ChemSpider	144027
UNII	K389NU4SEV
CompTox Dashboard (EPA)	DTXSID80926057
Chemical and physical data
Formula	C19H20N2O4
Molar mass	340.379 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CCC2=CC(=C(C=C2[C@H](C1)C3=CC=CC4=C3OCC4)O)[N+](=O)[O-]
InChI InChI=1S/C19H20N2O4/c1-20-7-5-13-9-17(21(23)24)18(22)10-15(13)16(11-20)14-4-2-3-12-6-8-25-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1 Key:XZPSYCOYKJRHKE-MRXNPFEDSA-N

Subsequently, NNC 01-0687 was developed under the code name ADX-10061 for treatment of substance dependence and was studied for smoking cessation, alcohol dependence, and cocaine dependence.^[3] It was also developed for treatment of sleep disorders.^[1] However, development for all of these indications was also discontinued, by 2007, and the drug was never marketed for any use.^[1]

NNC 01-0687 was first described in the scientific literature by 1992.^[5]

See also

• Berupipam (NNC 22-0010)
• Ecopipam (SCH-39166)
• Odapipam (NNC 01-0756)
• SCH-23390